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Total deficiency of complement factor H (CFH) is associated
with dense deposit disease and atypical hemolytic uremic
syndrome. CFH is the major regulator of the alternative
pathway of complement activation and its complete
deficiency results in uncontrolled C3 activation through this
pathway and secondary C3 deficiency. Plasma infusion, as a
source of CFH, has been used with variable success to treat
renal disease associated with its deficiency. However, the
risks of volume and protein overload limit this therapeutic
approach. In this study, we investigated the efficacy of a
purified human CFH (hCFH) preparation in Cfh-gene
knockout mice. These mice spontaneously develop both
secondary plasma C3 deficiency and a renal abnormality
characterized by massive accumulation of C3 along the
glomerular basement membrane. The renal lesion is
analogous to human dense deposit disease. Treatment of
knockout mice with hCFH resulted in rapid normalization of
plasma C3 levels and resolution of the glomerular basement
membrane C3 deposition. Long-term treatment of mice with
hCFH was not possible because of the development of an
immune response against hCFH. Hence, we suggest that
hCFH can be an effective alternative therapy to plasma
infusions in patients with renal disease associated with CFH
deficiency.
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Complete deficiency of complement factor H (CFH) is
associated with dense deposit disease (DDD) and atypical
hemolytic uremic syndrome (aHUS). DDD is characterized
by the presence of intra-membranous electron-dense trans-
formation of the glomerular basement membrane (GBM).1
The light microscopic features of DDD are heterogeneous but
include membranoproliferative inflammation. DDD is asso-
ciated with uncontrolled activation of the complement
alternative pathway (AP).1 The key AP regulator is the
plasma protein CFH. Complete genetic deficiency of CFH,
results in uncontrolled AP activation and severe secondary
C3 deficiency (reviewed in Pickering and Cook2). Complete
deficiency is also associated with DDD.3 DDD is also
associated with other causes of AP dysregulation, including
autoantibodies that inhibit CFH function,4,5 dysfunctional
C3 molecules,6,7 and autoantibodies that stabilize the AP C3-
cleaving enzyme complex (C3 nephritic factors).8,9 Animal
models have reinforced the importance of uncontrolled
AP activation in DDD. Gene-targeted CFH-deficient mice
(Cfh/) spontaneously develop low plasma C3 levels and
deposition of C3 along the murine GBM.10–12 This results in
electron-dense GBM change and glomerular inflammation. A
spontaneous mutation resulted in a breed of CFH-deficient
pigs that develop both low plasma C3 levels and membra-
noproliferative glomerulonephritis (MPGN).13–17
At present, there is no definitive therapy for DDD.1 The
condition is associated with end-stage renal failure in a
significant proportion of patients and has a very high
recurrence rate in renal transplants.1,18 Studies in Cfh/
mice showed that activation of the AP is essential for the
renal disease to develop. Thus, Cfh/ mice that are rendered
deficient in the AP activation protein factor B, do not develop
renal disease (reviewed in Pickering and Cook2). Sequential
histological studies in both pig and mouse models showed
that the initial renal histological abnormality was the
deposition of C3 along the GBM.10,16 These observations
suggest that key properties of an effective therapy in DDD
would include the ability to regulate AP activation and to
facilitate the removal of C3 along the GBM. An obvious
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definitive therapeutic in CFH deficiency is CFH itself.
Previously, we administered purified mouse CFH (mCFH)
to Cfh/ animals.19 This resulted in the removal of C3 along
the GBM, with concomitant increase in plasma C3 levels over
a relatively rapid time frame of 24 h. In this study, we
examined the efficacy of human CFH (hCFH) in the Cfh/
mouse model. Our data show that administration of hCFH to
Cfh/ mice resulted in rapid normalization of plasma C3
levels and resolution of GBM C3 deposits. These data suggest
that hCFH will be an effective therapy in individuals with
DDD associated with CFH dysfunction. Long-term assess-
ment of hCFH in mice was not possible because of the
development of an immune response against hCFH.
RESULTS
Administration of hCFH restored plasma AP regulation in
Cfh/ mice
Cfh/ mice spontaneously develop secondary C3 defi-
ciency.10 Hence, we first tested the ability of hCFH to restore
AP regulation by measuring plasma C3 levels after hCFH
administration. A single injection of 0.5mg hCFH intraper-
itoneally increased plasma C3 levels at 2 h, peaking at 24 h, at
which time the plasma C3 levels were comparable with
normal wild-type C3 levels (Figure 1a). In injected Cfh/
mice, plasma C3 levels remained normal at 48 h decreasing to
B50% of normal levels by 72 h and dropping to baseline
values by 96 h (Figure 1b). We next determined the activation
status of the plasma C3 by performing western blot analysis
for C3 under reducing conditions using serum obtained from
hCFH-injected mice. This enabled us to differentiate between
intact C3 and its activation products. Intact C3 a-chain and
b-chain were detectable in hCFH-injected Cfh/ mice
(Figure 1c). Intact C3 a-chain, absent in phosphate-buffered
saline (PBS)-injected Cfh/ mice, was detected as early as
2 h after administration of hCFH (Figure 1c). These data
showed that, in this heterologous in vivo system (hCFH,
mouse C3, and mouse CFI), hCFH was able to restore plasma
AP regulation in Cfh/ mice.
The serum half-life of hCFH was influenced by the degree of
C3 activation
We measured hCFH levels by enzyme-linked immunosorbent
assay (ELISA) before and at 24, 48, 72, 96, and 192 h (day 8)
after the intraperitoneal administration of 0.5mg hCFH
(Figure 1d). In Cfh/ mice (n¼ 4), serum hCFH levels were
highest in the 24 h samples (median 75.3mg/l, range
63.6–85.9) and decreased to very low levels by 96 h (median
5.6mg/l, range 2.9–6.7). hCFH was undetectable by day 8.
In parallel, we administered an identical dose of hCFH to
C3-deficient Cfh/ mice (Cfh/.C3/, n¼ 3). At each
time point, the median levels of hCFH were higher in
Cfh/.C3/ mice than in mice deficient in CFH alone. At
96 h, significant levels of hCFH were still detectable in
Cfh/.C3/ mice (31.6mg/l, range 28.5–31.9, n¼ 3)
compared with very low levels in Cfh/ animals (median
5.6mg/l, Po0.0001, Student’s t-test). In both groups of mice,
levels were undetectable at day 8. These data indicated that
the serum half-life of hCFH was critically dependent on the
degree of AP activation.
Administration of hCFH resulted in a rapid alteration in
glomerular C3 staining in Cfh/ mice
We next assessed renal C3 staining in Cfh/ mice 24 h after a
single intraperitoneal injection of 0.5mg hCFH. Cfh/ mice
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Figure 1 |Plasma C3 levels in Cfh/ mice injected with hCFH. (a, b) Mouse serum C3 levels at different time points after a single
intraperitoneal injection of either 0.5mg hCFH (filled circles) or an equivalent volume of PBS (open circles). Panels a and b represent two
separate experiments. Horizontal bars denote median values. Asterisk (*) denotes P¼ 0.0286, Mann–Whitney test. In this ELISA pooled
normal wild-type C3 level was 420mg/l. (c) Representative western blot of sera under reducing conditions for C3 from a Cfh/ animal
injected with hCFH. (d) Serum hCFH levels after a single intraperitoneal injection of 0.5mg hCFH into Cfh/ (n¼ 4, squares, solid line) and
Cfh/.C3/ (n¼ 3, triangles, dotted line) mice. Data points represent mean±s.d. Asterisk (*) denotes Po0.05, Student’s t-test. ELISA,
enzyme-linked immunosorbent assay; hCFH, human complement factor H; PBS, phosphate-buffered saline.
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have marked C3 deposition along the GBM.10 This is evident
on immunohistochemistry by a linear capillary wall glome-
rular staining distribution. In contrast, no staining for C3 is
seen within the glomerular mesangium or tubulointerstitial
areas. In vitro analysis of C3 isolated from laser-dissected
Cfh/ glomerular tissue showed that GBM-associated C3
included the C3 fragment iC3b, either in isolation or in
addition to C3d.19 Using either anti-C3 or anti-C3d
antibodies, linear capillary wall staining was evident in
untreated Cfh/ animals (Figure 2).19 Twenty-four hours
after hCFH injection, there was a marked alteration in
glomerular and tubulointerstitial C3 staining patterns. There
was a significant reduction in both the intensity and the extent
of glomerular capillary wall C3 reactivity using the anti-C3
antibody. Furthermore, mesangial C3 reactivity was now
evident together with reactivity within the tubulointerstitium.
In contrast, there was no change in the glomerular C3
reactivity pattern using the anti-C3d antibody. These changes
(scored in Table 1 and illustrated in Figure 2) are similar to
those that we have observed after a single injection of mCFH.19
Renal immunostaining for hCFH showed only weak glomer-
ular reactivity (data not shown). Notably, we did not detect
any evidence of glomerular neutrophil accumulation in Cfh/
mice reconstituted with hCFH, a phenomenon that was
observed when we administered mCFH to Cfh/ animals.19
In Cfh/ mice that had received a single injection of 0.5mg
hCFH and then killed 8 days later, renal C3 immunostaining
(using either anti-C3 or anti-C3d antibodies) showed linear
capillary wall GBM reactivity identical to Cfh/mice that had
received PBS (data not shown). This suggested that C3 had
reappeared along the GBM as serum levels of the injected
hCFH decreased (Figure 1d). We next assessed the effects of
repeated hCFH administration.
24 h post PBS injection 24 h post hCFH injection
C3
C3d
Figure 2 |Representative images of C3 immunostaining in
Cfh/ mice 24h after the injection of hCFH (right panel) or PBS
(left panel). In PBS-injected animals, capillary wall staining using
both anti-C3 and anti-C3d antibodies is evident from the linear
staining pattern outlining the glomerular capillary walls. No staining
of the tubulointerstitium is seen with either of these antibodies. In
hCFH-injected animals, the pattern of reactivity with the anti-C3
antibody showed that the capillary wall staining had markedly
reduced with concomitant appearance of reactivity within mesangial
(examples indicated by arrows) and tubulointerstitial areas. In
contrast, the administration of hCFH did not alter the staining pattern
seen with the anti-C3d antibody. Original magnification  20. hCFH,
human complement factor H; PBS, phosphate-buffered saline.
Table 1 | Serological and renal parameters after administration of hCFH to Cfh/ mice
Time of killing 24h 5 days 10 days
Single 0.5mg hCFH Daily 0.5mg hCFH Daily 0.5mg hCFH
hCFH dosinga hCFH (n=4) Control (n=4) hCFH (n=5) Control (n=3) hCFH (n=4) Control (n=6)
Serological analysis
Urea—mmol/l NA NA 9.2 (6.1–13.2) 14 (9.4–15) 44.4 (43.3–44.6)b 9.5 (6.4–15.3)
Serum C3 levels—mg/l 370 (308–515)b 60 (7–71) 402 (381–423)b 16 (12–19) 105 (76–140)b 25 (11–48)
Anti-hCFH antibodies—AEU NA NA Negative Negative 11.5 (11–12.8) Negative
Renal C3 immunostaining
Capillary wall intensity (0–3) 0.9 (0.7–1)b 2.6 (2.3–2.6) Negative 3 (2.5–3) 0.8 (0.8–0.9)b (2.7–3)
Capillary wall extent (0–4) 1.4 (0.8–1.9)b 3.8 (3.1–4) Negative 4 (4–4) 1.1 (0.9–1.6)b 3.8 (3.7–4)
Mesangium (0–4) 1.8 (1.5–2.1) Negative 0.1 (0–0.3) Negative 1.2 (1–1.4) Negative
Tubulointerstitium (0–3) 1.5 (1.5–2) Negative 2 (1.5–2.5) Negative 2 (1.5–2) Negative
Renal C3d immunostaining
Capillary wall intensity (0–3) 2.5 (2.3–2.5) 2.3 (2.2–2.6) 0.7 (0.6–1)b 2.5 (1.4–2.6) 1.2 (0.6–1.4)b 2.6 (2.4–2.9)
Capillary wall extent (0–4) 3.9 (3.3–4) 3.8 (3.4–4) 1 (0.9–1.3)b 3.4 (1.8–3.5) 1.7 (1.1–2.1)b 3.4 (3.3–3.8)
Mesangium (0–4) Negative Negative Negative Negative 0.2 (0–0.4) 0 (0–0.2)
Tubulointerstitium (0–3) Negative Negative 1 (0.5–1.5) Negative 2 (1–3)c Negative
Renal IgG immunostaining
Glomerular (0–3) Negative Negative Negative Negative 2.1 (1.8–2.4) Negative
Tubulointerstitium (0–3) Negative Negative Negative Negative Negative Negative
Abbreviations: AEU, arbitrary enzyme-linked immunosorbent assay unit; hCFH, human complement factor H; NA, not assessed; PBS, phosphate-buffered saline.
Values represent median with range of values in parentheses.
ahCFH administered by intraperitoneal injection.
bPo0.05 versus PBS control group, Mann–Whitney test.
cPo0.05 versus value at 5 days, Bonferroni’s test.
Kidney International (2010) 78, 279–286 281
F Fakhouri et al.: Treatment of factor H deficiency o r ig ina l a r t i c l e
Short-term administration of hCFH resulted in normalization
of glomerular C3 reactivity and a significant reduction in
glomerular C3d reactivity
We administered 0.5mg hCFH intraperitoneally daily
for 5 days to Cfh/ mice to determine whether repeated
dosing would normalize renal C3 immunostaining. Control
animals received intraperitoneal injections of an equivalent
volume of PBS. Serum C3 levels at the time of killing (24 h
after the final hCFH dose) were comparable with those
observed in normal C57BL/6 mice (Table 1). Serum urea
remained normal (Table 1) and no glomerular neutrophil
accumulation was seen. Striking changes were noted when we
examined glomerular C3 reactivity. Glomerular reactivity
with anti-C3 antibodies was now negative along capillary
walls, and mesangial staining was barely detectable (Table 1,
Figure 3). Furthermore, for the first time, we were now able
to detect a significant reduction in glomerular C3d reactivity
(Table 1, Figure 3). In hCFH-injected animals, some areas
within the tubulointerstitium reacted with the anti-C3d
antibody (Figure 3, arrows). We next assessed whether
longer-term administration of hCFH could completely
remove glomerular C3d deposits by increasing the treatment
period to 10 days.
Long-term administration of hCFH to Cfh/ mice
results in the generation of murine anti-hCFH antibodies
triggering immune-complex glomerulonephritis with
renal failure
Animals were injected intraperitoneally with either 0.5mg
hCFH (n¼ 4) or an equivalent volume of PBS (n¼ 6) daily
for 10 days. Unexpectedly, albuminuria developed in all
hCFH-treated animals (median at day 10¼ 26.9mg/ml,
range 12–39.9), whereas it was undetectable in PBS-injected
animals. At the time of killing, all hCFH-treated animals were
uremic (median 44.4mmol/l, Table 1), whereas urea levels
were normal in control mice (median 9.5, Po0.05,
Mann–Whitney test). Renal histology showed florid glomer-
ular hypercellularity consistent with proliferative glomerulo-
nephritis (Figure 4b). There was marked deposition of IgG
within the glomeruli of all hCFH-injected animals (Table 1,
Figure 4c). Glomerular reactivity with anti-C3 antibodies,
which had been negative along capillary walls in Cfh/ mice
treated with hCFH for 5 days (Figure 3), was now strongly
positive in a staining pattern identical to IgG (Table 1,
Figure 4c). In contrast, glomerular C3d immunostaining
showed a significant reduction compared with control
animals (Table 1). When glomerular C3d staining was
compared with that seen in Cfh/ mice treated with hCFH
for 5 days, there was no significant difference in either the
intensity or the extent of C3d staining (Table 1). However,
tubulointerstitial staining for C3d was significantly increased
(Figure 4c and Table 1), leading us to speculate that GBM-
associated C3d was being removed through the urinary space.
However, we were unable to reliably demonstrate the
presence of C3 in the urine of hCFH-treated animals.
The presence of IgG within the kidney of hCFH-treated
mice suggested that Cfh/ animals had generated a mouse
anti-hCFH antibody response. This was further supported by
the observation that serum C3 levels at the time of killing
(24 h after the final hCFH injection) had not normalized but
were B25% of pooled wild-type C3 levels (median level
105mg/l, Table 1). Using an ELISA method, analogous to
that used to detect anti-CFH IgG autoantibodies in hu-
mans,20 mouse anti-hCFH antibodies were detected in all
four of the hCFH-treated Cfh/ mice (Table 1). These
antibodies were also detected using a far western blot assay
(data not shown). Antibodies were not detected in Cfh/
mice that had received hCFH over a period of 5 days
(Table 1). Serum hCFH could not be detected using western
blot at the time of killing (24 h after the final injection of
0.5mg hCFH). Our earlier experiments had shown that
hCFH was easily detectable at this time point after a single
injection (Figure 1d). In contrast, renal immunostaining
in hCFH-treated mice, revealed strong glomerular
hCFH staining in a pattern equivalent to that seen for IgG
(Figure 4c). These data confirmed the presence of mouse
anti-hCFH antibodies and suggested that antibodies result in
rapid clearance of injected hCFH from the circulation and
deposition of mouse IgG–hCFH immune complexes within
the kidney.
5 days post daily PBS injection
C3
C3d
5 days post daily hCFH injection
Figure 3 |Representative images of C3 immunostaining in
Cfh/ mice 5 days after daily injection of 0.5mg of hCFH
(right panel) or PBS (left panel). In PBS-injected animals,
capillary wall staining using both anti-C3 and anti-C3d
antibodies is evident by the linear staining pattern outlining
the glomerular capillary walls. No staining of the
tubulointerstitium is seen with either of these antibodies. In
hCFH-injected animals, the pattern of reactivity with the anti-C3
antibody showed that the capillary wall staining had completely
resolved. Furthermore, only minor and small areas of mesangial
staining (example indicated by arrow) remained compared with
that seen after 24 h (Figure 2). Normal tubulointerstitial C3
reactivity is also now present. The glomerular reactivity with the
anti-C3d antibody has significantly reduced, although is still
detectable. Furthermore, in hCFH-injected animals, some
areas within the tubulointerstitium react with the anti-C3d
antibody (examples indicated by arrows). Original magnification
 20. hCFH, human complement factor H; PBS, phosphate-
buffered saline.
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DISCUSSION
Administration of hCFH to Cfh/ mice resulted in the
restoration of plasma C3 levels together with the appearance
of intact C3 in the plasma. These observations are similar to
those that we reported when we administered mCFH to
Cfh/ mice.19 Furthermore, the rapid reduction in GBM C3
staining was also comparable with that which we observed in
Cfh/ mice treated with mCFH.19 These data demonstrated
that hCFH was capable of interacting efficiently with the
mouse factor I and mouse C3 in vivo. Our present findings
using hCFH and previous observations with mCFH19 showed
that a single injection of CFH markedly reduced GBM C3
reactivity but not reactivity to C3d in Cfh/ mice within
24 h. The reduction in GBM C3 reactivity was accompanied
by the appearance of mesangial C3 but not C3d reactivity,
suggesting that the mesangial C3 fragment was C3c. When we
administered repeated doses of hCFH, the GBM C3d
reactivity progressively decreased, so that after 10 days of
hCFH treatment, GBM C3d reactivity was markedly reduced
compared with untreated mice. Furthermore, after 10 days of
treatment with hCFH, C3d reactivity was seen within tubular
areas. These data led us to conclude that the administration
of hCFH restored plasma AP regulation, resulting in the
cessation of C3 deposition along the GBM in Cfh/ mice.
This enabled the clearance of GBM-associated C3, which we
have previously shown to be iC3b,19 to begin. We speculated
that GBM-associated iC3b is initially cleaved to C3d releasing
C3c to the mesangium. The remaining C3d is removed
several days after the onset of plasma AP regulation, most
likely through the urinary space. The removal of C3d from
the GBM within 10 days is rapid in comparison with the
estimated half-life of C3d associated with glomerular
immune complexes.21 In these studies, although glomerular
C3c was cleared within 24 h, glomerular C3d reactivity
remained unchanged 23 days after cessation of complement
activation. Finally, when we administered mCFH to Cfh/
mice, we noted accumulation of glomerular neutrophils, which
we considered a consequence of low levels of endotoxin in our
mCFH preparation.19 This interpretation is consistent with the
lack of glomerular neutrophil accumulation in this study in
which we used endotoxin-free hCFH.
Our data showed that the administration of hCFH over a
short time frame resulted in the clearance of C3 from the
GBM of Cfh/ mice. The appearance of C3 along the GBM
is the earliest pathological renal abnormality in both Cfh/
mice10 and Cfh/ pigs.16 Therefore, it might be expected
that clearance of GBM C3 would result in either amelioration
or prevention of glomerular inflammation and membrano-
proliferative changes. The potent and rapid development
of murine anti-hCFH antibodies prevented us from testing
the effects of long-term administration of hCFH on
either established renal inflammation or preventing the
development of such inflammation. However, despite the
development of an immune-complex glomerulonephritis,
administration of hCFH daily for 10 days resulted in a
significant loss of glomerular C3d reactivity. To our knowl-
edge, this is the first demonstration of a significant reduction
of C3d deposits in a DDD model after the administration of
an exogenous compound.
10 days post daily PBS injection
IgG
C3
C3d
HCFH
10 days post daily hCFH injection
Figure 4 |Renal histology after 10 days administration of
hCFH. Representative light microscopic images of Cfh/ mice
10 days after daily injection of (a) PBS or (b) 0.5mg hCFH.
Glomerular inflammation and protein casts are evident in animals
treated with hCFH (panel b) in contrast to the absence of these
changes in mice treated with PBS (panel a); original magnification
 20. (c) Representative images of IgG, C3, C3d, and hCFH
immunostaining in Cfh/ mice 10 days after daily injection of
0.5mg of hCFH (right panel) or PBS (left panel). In PBS-injected
animals, capillary wall staining using both anti-C3 and anti-C3d
antibodies shows a linear staining pattern outlining the
glomerular capillary walls. No staining for mouse IgG is evident
and only slight staining for hCFH is seen, most likely reflecting
cross-reactivity with mouse CFH-related proteins.19 In contrast
florid glomerular staining for mouse IgG, C3, and hCFH is seen
in animals treated with hCFH. Glomerular C3d immunostaining
remains reduced compared with control animals (glomeruli
indicated by arrow) and comparable with that seen after 5 days
of hCFH treatment (Figure 3). In contrast, tubulointerstitial
C3d staining in hCFH-treated mice is more marked. Original
magnification  20. hCFH, human complement factor H;
PBS, phosphate-buffered saline.
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Experimental data obtained from Cfh/mice have shown
that restoring AP regulation can reverse GBM C3 staining:
transplantation of the kidneys from Cfh/ mice into wild-
type recipients resulted in complete normalization of
glomerular C3 staining.22 In Cfh/ pigs, a single 30ml/kg
plasma or 5mg/kg porcine CFH infusion increased plasma
C3 levels and reduced soluble plasma terminal complement
complex levels for B3 days.14 Weekly plasma infusions to
Cfh/ pigs (from the age of 2 weeks) resulted in improved
survival (median survival was 37 and 82 days, treated versus
non-treated, respectively).14 Renal histology in treated Cfh/
pigs showed the persistence of membranoproliferative
changes, although the severity of the lesions was less when
compared with untreated animals.14
Reports of plasma therapy in individuals with complete
CFH deficiency and DDD are rare. Two patients with DDD in
association with C3 nephritic factor and homozygous CFH
mutation were reported to have stable renal function when
treated with fortnightly plasma infusions (10–15ml/kg) for a
total of 36 months.23,24 One patient developed hematuria
after upper airways infection, which responded to additional
plasma infusions.23 aHUS is empirically treated with plasma
therapy (plasma exchange or plasma infusion).25 For
individuals with aHUS associated with complete CFH
deficiency, plasma infusions have been beneficial in main-
taining remission and treating relapses in some cases,26–28
whereas in others, the response was variable29 or poor.30,31 In
one individual with aHUS and CFH deficiency, successfully
treated with weekly plasma infusions over a 4-year period, a
plasma-resistant relapse developed.32 The reason for this was
not clear, but importantly anti-CFH antibodies were not
present. It seems reasonable to conclude that although the
development of mouse anti-hCFH antibodies in the absence
of adjuvant was rapid, the observed immunogenicity of
the hCFH in Cfh/ animals in our study was most likely the
consequence of the human origin of the injected CFH.
Serial CFH measurements in one CFH-deficient indivi-
dual with aHUS successfully treated with repeated infusions
of plasma, suggested a serum CFH half-life of 6 days.27 After
infusion of 20ml/kg plasma, serum CFH increased from
undetectable levels to 110 mg/ml, decreasing by 50% 6 days
after the infusion.27 Our data suggest that the serum half-life
of hCFH is influenced by the degree of C3 activation. hCFH
was detectable in the plasma for a greater duration in mice
with combined deficiency of CFH and C3 than in mice
deficient in CFH alone. The half-life of CFH seems likely to
vary according to the extent of C3 activation. This may be
important for dosing studies in humans with DDD who may
have distinct causes of AP dysregulation associated with
quantitatively different degrees of AP dysregulation.
In conclusion, the impressive results obtained over the
short-term administration of hCFH in this murine model of
DDD suggest that hCFH is a promising therapy for human
DDD associated with CFH deficiency. The advantage of
purified CFH concentrate is that it should be possible to
administer the amount of CFH required to normalize AP
regulation without concerns of excessive volume and protein
load that limit plasma therapy. Further studies will be
required to address efficacy over the longer term and to
investigate whether administration of exogenous hCFH is of
benefit to individuals with DDD driven by causes other than
CFH deficiency.
MATERIALS AND METHODS
Animals
Cfh/ mice were generated as described previously.10 All experi-
ment animals were age- and sex-matched and were bred on the
C57BL/6 genetic background for at least 10 generations. All
experimental procedures were conducted in accordance with
institutional guidelines.
Human complement factor H
hCFH was provided by LFB (Laboratoires Franc¸ais de Fractionne-
ment et des Biotechnologies, Paris, France), a French pharmaceutical
company specializing in plasma-derived medicinal products. The
human plasma-derived factor H concentrate was purified by
multistep chromatography. The purification process included both
viral inactivation by solvent detergent treatment (a process that
inactivates lipid-enveloped viruses) and viral segregation using a
sequence of nanofilters that remove small viruses and prions.
Administration of hCFH to Cfh/ mice
Animals were injected intraperitoneally with 0.5mg of hCFH or an
identical volume of PBS. Mice were killed at the indicated time
points after injection and plasma and renal tissues were collected for
analysis.
Detection of hCFH
Plasma hCFH was detected by western blot using a polyclonal goat
anti-hCFH antibody (Quidel, San Diego, CA, USA). hCFH was
quantified by ELISA using a monoclonal anti-hCFH capture
antibody (Quidel) and a polyclonal goat anti-hCFH detection
antibody (Quidel).
Measurement of mouse C3
Mouse C3 levels were measured by ELISA using goat anti-mouse C3
antibody (MP Biomedicals, Solon, OH, USA) as described
previously.10 Results were quantified by reference to a standard
curve generated from acute-phase sera containing a known quantity
of C3 (Calbiochem, Nottingham, UK).
Measurement of mouse urea and albuminuria
Serum urea was measured using a UV method kit (R-Biopharm
Rhone, Glasgow, UK) according to manufacturer’s instructions.
Albuminuria was measured by radial immunodiffusion as described
previously.10
Detection of murine anti-hCFH antibodies
Murine anti-hCFH antibodies were detected by ELISA. Nunc
MaxiSorp ELISA plates (Nunc, Roskilde, Denmark) were coated
with 0.3mg of hCFH diluted in 0.1mol/l NaHCO3 pH 9.5.
After washing and blocking free reactive sites with 1% bovine
serum albumin in PBS, the plasma to be tested was added at a
dilution of 1:200 and incubated for 1 h at room temperature. After
washing, the plates were incubated for 1 h at room temperature with
a goat anti-murine IgG antibody labeled with horseradish
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peroxidase (Sigma-Aldrich, Steinheim, Germany). After additional
washing, enzymatic activity was revealed using an orthophenyldia-
mine substrate. Antibody titers were expressed as arbitrary ELISA
units calculated as optical density of the test sample  200. We also
detected murine anti-hCFH antibodies using a far western blot
technique. Murine sera were separated using SDS-acrylamide gel
(8%) under nonreducing conditions. After transfer to the protein
membrane, the membrane was incubated with a solution containing
hCFH at a concentration of 10 mg/ml for 2 h. After washing, the
membrane was then incubated with goat anti-hCFH antibody
(Quidel), and bound antibody was detected by incubation with
horseradish peroxidase-conjugated rabbit anti-goat IgG (Sigma, St
Louis, MO, USA).
Histological studies
Kidneys were fixed in Bouin’s solution (Sigma, Gillingham, UK) and
paraffin sections were stained with periodic acid-Schiff reagent.
Glomerular histological analysis was performed in a blinded manner
as described previously.10 In all, 50 glomeruli were analyzed per
section. For immunostaining, snap-frozen renal tissue sections were
used. Mouse C3 was detected using either fluorescein isothiocya-
nate-conjugated goat anti-mouse C3 (MP Biomedicals) or an
unconjugated polyclonal goat anti-mouse C3 antibody (Abcam,
Cambridge, UK), followed by a secondary Texas red-labeled
polyclonal rabbit anti-goat antibody (Abcam). Mouse C3d staining
was detected using a biotinylated-goat anti-mouse C3d (R&D
Systems, Abingdon, UK) and a secondary Streptavidin-PE conjugate
(Euro Bioscience GmbH, Friesoythe, Germany). Previously, we have
shown that the anti-C3d antibody reacted with tissue-associated
C3d but not C3b or native C3. In contrast the anti-C3 antibody
recognized native C3 and all C3 fragments, except tissue-associated
C3d.19,33 hCFH was detected using a fluorescein isothiocyanate-
conjugated polyclonal goat anti-hCFH antibody (Quidel).
Immunofluorescence staining was assessed in a blinded manner on
the basis of its intensity in glomerular and interstitial structures and its
extent along the glomerular capillary walls. Intensity was quantified
using the following semi-quantitative scale: 0 (negative), 1 (mild),
2 (moderate), and 3 (intense). The extent of immunofluorescence
staining along the glomerular capillary walls was quantified as the
percentage of the entire capillary walls in each glomerulus with
a positive immunofluorescence staining: 0 (0%), 1 (1–25%), 2
(26–50%), 3 (51–75%), and 4 (76–100%). Therefore, each glomerulus
had an immunofluorescent intensity and an immunofluorescent
extent score. For each kidney section, 50 glomeruli were examined and
scored, and the average score recorded.
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